The ATLAS Drug Eluting Coronary Stent System is a next-generation cobalt-chromium (CoCr) stent platform coated with a sirolimus formulation (1 µg/mm²) designed to reduce restenosis in patients with coronary artery disease. By combining advanced laser-cutting technology and a clinically proven antiproliferative drug, the ATLAS system delivers durable vessel patency and a high safety profile in both de novo lesions and in-stent restenosis scenarios.
Cobalt-Chromium Alloy (L605) Construction
- Ensures exceptional strength-to-thickness ratio, enabling thinner struts without compromising radial force.
- Exhibits excellent corrosion resistance and biocompatibility for a stable healing environment.
Laser-Cut Stent Design
- Precision machining yields consistent strut geometry, promoting uniform drug distribution and an even healing surface along the vessel wall.
- Enhances stent deliverability, allowing smooth passage through calcified or tortuous coronary segments.
Sirolimus Elution Profile
- 1 µg/mm² of sirolimus is coated onto the stent’s surface, ensuring a sustained, controlled release that minimizes in-stent neointimal growth.
- Controlled drug release aids in rapid endothelialization, lowering the risk of late stent thrombosis.
Radiopaque Pt-Ir Markers
- Platinum-iridium markers at stent edges enable precise visibility under fluoroscopy.
- Facilitates accurate positioning during percutaneous coronary intervention (PCI) procedures.
High-Pressure Capability
interventional cardiologists flexibility to optimize stent expansion based on lesion complexity.
- Ensures exceptional strength-to-thickness ratio, enabling thinner struts without compromising radial force.
- Exhibits excellent corrosion resistance and biocompatibility for a stable healing environment.
- Precision machining yields consistent strut geometry, promoting uniform drug distribution and an even healing surface along the vessel wall.
- Enhances stent deliverability, allowing smooth passage through calcified or tortuous coronary segments.
- 1 µg/mm² of sirolimus is coated onto the stent’s surface, ensuring a sustained, controlled release that minimizes in-stent neointimal growth.
- Controlled drug release aids in rapid endothelialization, lowering the risk of late stent thrombosis.
- Platinum-iridium markers at stent edges enable precise visibility under fluoroscopy.
- Facilitates accurate positioning during percutaneous coronary intervention (PCI) procedures.
interventional cardiologists flexibility to optimize stent expansion based on lesion complexity.